Cargando…
Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
BACKGROUND: Patients with cancer‐associated venous thromboembolism (VTE) are recommended to receive treatment with therapeutic anticoagulation for at least 3–6 months. Little data exist on extended treatment beyond 6 months. OBJECTIVE: To comprehensively summarize the best available evidence on inci...
Autores principales: | Moik, Florian, Colling, Meaghan, Mahé, Isabelle, Jara‐Palomares, Luis, Pabinger, Ingrid, Ay, Cihan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299994/ https://www.ncbi.nlm.nih.gov/pubmed/34816583 http://dx.doi.org/10.1111/jth.15599 |
Ejemplares similares
-
Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
por: Moik, Florian, et al.
Publicado: (2020) -
Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022) -
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
por: Nopp, Stephan, et al.
Publicado: (2020) -
How I treat cancer-associated thrombosis
por: Moik, Florian, et al.
Publicado: (2020) -
Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)